Bristol Myers Squibb has become the latest Big Pharma to tie up a biotech pact as we reach the year’s end, tapping Harbour ...

Harbour is eligible for payments of $90m, with potential development and commercial milestones of up to $1.035bn.

NEW HOPE, Pa., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to ...

Joint presentation by Orchestra BioMed and Medtronic leadership to discuss ongoing strategic collaboration for development and commercialization ...

RICHMOND — Edison High School Biomed IV students put on their thinking caps and created ways to optimize emergency rooms ...

Orchestra BioMed has announced that the FDA has granted Breakthrough Device Designation for its atrioventricular interval modulation (AVIM) therapy, aimed at treating over 7.7 million U.S. patients ...

Sino-US biotech Harbour BioMed, which is focused on the discovery and development of novel antibody therapeutics in ...

True to its name, Orchestra BioMed is currently conducting a symphony of several business ventures at once. In a three-in-one announcement Tuesday, the Pennsylvania-based startup unveiled a new ...

Harbour BioMed has entered a strategic partnership with Otsuka Pharmaceutical focusing on the development of HBM7020, a B-cell maturation antigen (BCMA) xcluster [cross cluster] of differentiation 3 ...

Harbour BioMed announced it has entered a multi-year, global strategic collaboration and license agreement with Bristol Myers ...

SAN ANTONIO – The Texas Biomedical Research Institute has withdrawn its $11 million request for bond funding in the face of public outcry over animal welfare concerns. Texas Biomed had requested money ...